Affymetrix Appoints Rick Runkel to Executive Vice President and General Counsel
October 20 2008 - 4:30PM
Business Wire
Affymetrix Inc. (Nasdaq:AFFX) today announced the addition of John
F. (Rick) Runkel to its management team as Executive Vice President
and General Counsel. �Rick has been a successful lawyer for 25
years and brings a wealth of experience to our leadership team,�
said Kevin King, president of Affymetrix. �We are very pleased to
add Rick and look forward to his contributions in developing and
implementing our corporate legal strategy.� Prior to joining
Affymetrix, Runkel served as senior vice president and general
counsel at Intuitive Surgical Inc, a leader in surgical robotics.
Prior to that, he was senior vice president of business
development, general counsel and corporate secretary at VISX Inc.,
a leader in laser vision correction technology. In addition, Runkel
spent 17 years practicing law at Sheppard, Mullin, Richter and
Hampton LLP, where he was managing partner of the firm�s San
Francisco office. �Affymetrix is a company that continues to
revolutionize life by powering genetic breakthroughs and enabling
individuals to benefit from their own DNA,� said Runkel. �I look
forward to being a part of such a quality organization with one of
the industry�s strongest IP portfolios.� Runkel received his law
and undergraduate degrees from the University of California, Los
Angeles. About Affymetrix: Affymetrix GeneChip� microarray
technology is the industry-standard tool for analyzing complex
genetic information. After inventing microarray technology in the
late 1980s, Affymetrix scientists have been dedicated to developing
innovative products that provide researchers with a more complete
view of the genome. These products continue to accelerate genetic
research and enable scientists to develop diagnostics and tailor
treatments for individual patients by identifying and measuring the
genetic information associated with complex diseases. Today,
Affymetrix technology is used by the world�s top pharmaceutical,
diagnostic and biotechnology companies, as well as leading
academic, government and not-for-profit research institutes. More
than 1,700 systems have been shipped around the world and more than
14,000 peer-reviewed papers have been published using the
technology. Affymetrix is headquartered in Santa Clara, Calif., and
has manufacturing facilities in Sacramento, Calif., Cleveland,
Ohio, and Singapore. The company has about 1,100 employees
worldwide and maintains sales and distribution operations across
Europe and Asia. For more information about Affymetrix, please
visit the company�s website at www.affymetrix.com. Forward-looking
Statements All statements in this press release that are not
historical are �forward-looking statements� within the meaning of
Section 21E of the Securities Exchange Act as amended, including
statements regarding Affymetrix� �expectations,� �beliefs,�
�hopes,� �intentions,� �strategies� or the like. Such statements
are subject to risks and uncertainties that could cause actual
results to differ materially for Affymetrix from those projected,
including, but not limited to: risks and uncertainties associated
with the management changes discussed in this press release; risks
of the company�s ability to achieve and sustain higher levels of
revenue, higher gross margins and reduced operating expenses;
uncertainties related to technological approaches, manufacturing
and product development; personnel retention; uncertainties related
to cost and pricing of Affymetrix products; dependence on
collaborative partners; uncertainties related to sole-source
suppliers; risks associated with past and future acquisitions;
uncertainties relating to FDA and other regulatory approvals;
competition; risks relating to intellectual property of others and
the uncertainties of patent protection and litigation. These and
other risk factors are discussed in Affymetrix� Form 10-K for the
year ended December 31, 2007, and other SEC reports, including its
Quarterly Reports on Form 10-Q for subsequent quarterly periods.
Affymetrix expressly disclaims any obligation or undertaking to
release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in Affymetrix�
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are based.
NOTE: Affymetrix, the Affymetrix logo and GeneChip� are registered
trademarks owned or used by Affymetrix Inc.
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jul 2023 to Jul 2024